FDA Delays Field Reorganization to Study Possible Impact on Imports
This article was originally published in The Gold Sheet
Concerns about imports delay FDA’s massive field reorganization.
You may also be interested in...
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.